

Preliminary Amendment
Attorney Docket No. Q95329
USSN: 10/581,619

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:


Claims 1-5. (Canceled)

6. **(Original)** A medicament combined a prostaglandin-like compound having weak blood pressure-lowering effect, excluding limaprost, with one or more selected from prostaglandins, prostaglandin derivatives, nonsteroidal anti-inflammatory drugs, vitamins, muscle relaxants, antidepressants, nitric oxide synthase inhibitors, aldose reductase inhibitors, poly ADP-ribose polymerase inhibitors, excitatory amino acid receptor antagonists, radical scavengers, astrocyte modulators, phosphodiesterase inhibitor and immunosuppressive drugs.

7. **(Original)** A method for increasing cauda equina blood flow, which comprises administering to a mammal an effective amount of a prostaglandin-like compound having weak blood pressure-lowering effect, excluding limaprost.

Claim 8. (Canceled)

9. **(Original)** A compound represented by formula (I-1)



wherein ring A¹ is 5 or 6 membered nitrogen-containing mono-heterocyclic ring may have a substituent(s), and the ring A¹ may comprise, in addition, nitrogen, oxygen and/or sulfur,
E¹ is optionally oxidized sulfur,
Y is nitrogen or carbon,
W is hydrocarbon group which may have a substituent(s),

Preliminary Amendment
Attorney Docket No. Q95329
USSN: 10/581,619

a salt thereof, an N-oxide thereof, a solvate thereof or prodrug thereof, or a cyclodextrin clathrate thereof.

10. **(Original)** The compound according to Claim 9, which is selected from
2-{[2-((4S)-4-((1E,3R)-3-[1-(4-fluorobutyl)cyclobutyl]-3-hydroxy-1-propenyl)-2-oxo-1,3-oxazolidin-3-yl)ethyl]sulfanyl}-1,3-thiazole-4-carboxylic acid (compound 8-1),
2-{[2-((4S)-4-((1E,3R)-8-fluoro-3-hydroxy-4,4-dimethyl-1-octenyl)-2-oxo-1,3-oxazolidin-3-yl)ethyl]thio}-1,3-thiazole-4-carboxylic acid (compound 8-6),
2-{[2-((4S)-4-((1E,3R)-3-hydroxy-3-[1-(3-methoxypropyl)cyclobutyl]-1-propenyl)-2-oxo-1,3-oxazolidin-3-yl)ethyl]sulfanyl}-1,3-thiazole-4-carboxylic acid (compound 32-2),
2-{[2-((4S)-4-((1E,3R)-3-[1-(2-cyclohexylethyl)cyclobutyl]-3-hydroxy-1-propenyl)-2-oxo-1,3-oxazolidin-3-yl)ethyl]sulfanyl}-1,3-thiazole-4-carboxylic acid (compound 32-14),
2-{[2-((4S,5S)-4-((1E)-3-hydroxy-3-[1-(3-methoxypropyl)cyclobutyl]-1-propenyl)-5-methyl-2-oxo-1,3-oxazolidin-3-yl)ethyl]sulfanyl}-1,3-thiazole-4-carboxylic acid (compound 34-6) and
2-{[2-((4S,5S)-4-((1E)-4-hydroxy-4-methyl-1-nonenyl)-5-methyl-2-oxo-1,3-oxazolidin-3-yl)ethyl]sulfanyl}-1,3-thiazole-4-carboxylic acid (compound 45).

11. **(Original)** (2E)-7-((1R,2R)-2-[(1E,3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl)-2-heptenoic acid (compound 24),
(2E)-7-((1R,2R,3R)-3-hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methyl-1-undecenyl]-5-oxocyclopentyl)-2-heptenoic acid (compound 25),
(2E)-7-((1R,2S)-2-[(1E,3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxo-3-cyclopenten-1-yl)-2-heptenoic acid (compound 26),
2-[(2-((1R,2R)-2-[(1E,3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl)ethyl]sulfanyl}-1,3-thiazole-4-carboxylic acid (compound 30),
2-[(2-((1R,2R)-2-[(1E,3R)-3-hydroxy-4,4-dimethyl-1-octenyl]-5-oxocyclopentyl)ethyl]sulfanyl}-1,3-thiazole-4-carboxylic acid (compound 30-1),
7-((1R,2R,3R)-3-hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl)-6-oxoheptanoic acid (compound 31),
2-[(2-((1R,2R)-2-[(1E)-5-cyclohexyl-4-hydroxy-4-methyl-1-pentenyl]-5-oxocyclopentyl)ethyl]sulfanyl}-1,3-thiazole-4-carboxylic acid (compound 53) or

Preliminary Amendment
Attorney Docket No. Q95329
USSN: 10/581,619


3-{2-[(2R)-2-[(1E,3R)-3-[1-(4-fluorobutyl)cyclobutyl]-3-hydroxy-1-propenyl]-5-oxo-1-pyrrolidinyl)methyl]-1,3-thiazol-4-yl}propanoic acid (compound 76),

a salt thereof, an N-oxide thereof, a solvate thereof or prodrug thereof, or a cyclodextrin clathrate thereof.

12. (New) The method according to Claim 7 wherein the prostaglandin-like compound is EP2 and/or EP3 agonist.

13. (New) The method according to Claim 7 which improves one or more selected from lumbago, lower limb pain, lower limb numbness, intermittent claudication, bladder and rectal disorder and sexual dysfunctions.

14. (New) The method according to Claim 7 wherein the prostaglandin-like compound is a compound represented by formula (I)



wherein ring A is 5 or 6 membered ring which may comprise at least one hetero atom selected nitrogen, oxygen and sulfur, and may have a substituent(s),

X and Y are each independently nitrogen or carbon, D is hydrocarbon group which may have a substituent(s),

E is a bond, oxygen or optionally oxidized sulfur,

G is a bond, hydrocarbon group which may have a substituent(s) or hetero ring which may have a substituent(s),


J is acidic group which may be protected,

W is hydrocarbon group which may have a substituent(s),

a salt thereof, an N-oxide thereof, a solvate thereof or prodrug thereof, or a cyclodextrin clathrate thereof.

15. (New) The method according to Claim 14 wherein the compound represented by formula (I) is a compound represented by (I-1)

Preliminary Amendment
Attorney Docket No. Q95329
USSN: 10/581,619



wherein ring A¹ is 5 or 6 membered nitrogen-containing mono-heterocyclic ring may have a substituent(s), and the ring A¹ may comprise, in addition, nitrogen, oxygen and/or sulfur,
E¹ is optionally oxidized sulfur,
Y is nitrogen or carbon,
W is hydrocarbon group which may have a substituent(s).